ASP Isotopes Q2 FY26 net loss narrows to $33.59 million; revenue rises 327.63% to $5.12 million
ASPI•ASPI•ASPI•ASPI•ASP Isotopes posted a GAAP net loss attributable to shareholders of $33.59 million, narrowing from $75.06 million a year earlier.
Revenue rose to $5.12 million, up 327.63% year over year, as radiopharmacy sales climbed to $3.9 million.
LNG sales added $654,000, while collaboration revenue from TerraPower contributed $600,000.
Research and development expense increased to $6.82 million, while selling, general and administrative costs climbed to $28.85 million.
Cash and cash equivalents totaled $219.6 million, with short-term investments of $35.3 million as of June 30, 2026.
